Revvity Inc. (NYSE:RVTY) said Wednesday it agreed to acquire France-based Human Cell Design, expanding its human cell-model portfolio for diabetes, obesity and other metabolic disease research.
The deal is expected to close in the fourth quarter of 2026, subject to regulatory approvals and other customary conditions. The companies did not disclose financial terms.
Revvity ended the second quarter of 2026 with cash and cash equivalents of $1.02 billion.
Deal Targets Growing Metabolic Drug Research
The acquisition will add Human Cell Design’s human pancreatic beta cell models to Revvity’s Life Sciences portfolio.
The technology supports drug screening and preclinical research, including work on GLP-1 and other metabolic disease therapies.
Human Cell Design’s flagship EndoC-βH5 model allows researchers to study human pancreatic beta cell function in diabetes and obesity. The company also offers specialized reagents, preclinical research services and its NatLine cell-line development platform.
See More:
Top Value Stocks
Revvity Expands Drug Discovery Platform
Revvity CEO Prahlad Singh said the deal will combine Human Cell Design’s models with Revvity’s screening, detection, automation and analysis technologies.
The models can work with Revvity’s HTRF, AlphaLISA and ATPlite assays, as well as its high-content screening platform.
The technology could also support regenerative medicine research for Type 1 diabetes and cell-based therapies as they move toward commercialization.
RVTY Price Action: Revvity shares were trading down 0.27% at $126.74 during premarket trading on Wednesday, according to Benzinga Pro data.
Photo via Shutterstock
